These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 39014160)

  • 1. Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy.
    Elkrief A; Méndez-Salazar EO; Maillou J; Vanderbilt CM; Gogia P; Desilets A; Messaoudene M; Kelly D; Ladanyi M; Hellmann MD; Zitvogel L; Rudin CM; Routy B; Derosa L; Schoenfeld AJ
    NPJ Precis Oncol; 2024 Jul; 8(1):143. PubMed ID: 39014160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.
    Attili I; Valenza C; Santoro C; Antonarelli G; Trillo Aliaga P; Del Signore E; Catania C; Spitaleri G; Passaro A; de Marinis F
    Front Oncol; 2022; 12():980765. PubMed ID: 36033444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Elkrief A; Riccuiti B; Alessi JV; Fei T; Kalvin HL; Egger JV; Rizvi H; Thummalapalli R; Lamberti G; Plodkowski A; Hellmann MD; Kris MG; Arcila ME; Baine MK; Rudin CM; Lito P; Ladanyi M; Schoenfeld AJ; Riely GJ; Awad MM; Arbour KC
    Oncologist; 2023 Nov; 28(11):978-985. PubMed ID: 37589215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
    Zhang X; Zhou Y; Chen H; Chen C; Lin Z; He LN; Du W; Chen T; Hong S; Fu S
    Front Immunol; 2022; 13():1015444. PubMed ID: 36248788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
    White MN; Piper-Vallillo AJ; Gardner RM; Cunanan K; Neal JW; Das M; Padda SK; Ramchandran K; Chen TT; Sequist LV; Piotrowska Z; Wakelee HA
    Clin Lung Cancer; 2022 May; 23(3):e210-e221. PubMed ID: 34887193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
    Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
    Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
    Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of antibiotic selection and interval time among advanced non-small cell lung cancer patients receiving prior antibacterial treatment and first-line chemotherapy.
    Tian X; Mei T; Yu M; Li Y; Ao R; Gong Y
    Cancer Med; 2022 Dec; 11(24):4849-4864. PubMed ID: 35543371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line immune-based combination therapies for advanced non-small cell lung cancer: A Bayesian network meta-analysis.
    Mao Z; Jiang P; Zhang Y; Li Y; Jia X; Wang Q; Jiao M; Jiang L; Shen Y; Guo H
    Cancer Med; 2021 Dec; 10(24):9139-9155. PubMed ID: 34747149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review.
    Li L; Xu F; Chen Y; Ren X; Liu Y; Chen Y; Xia S
    BMJ Open; 2020 Nov; 10(11):e034010. PubMed ID: 33444168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types.
    Kulkarni AA; Ebadi M; Zhang S; Meybodi MA; Ali AM; DeFor T; Shanley R; Weisdorf D; Ryan C; Vasu S; Rashidi A; Patel MR
    ESMO Open; 2020 Sep; 5(5):e000803. PubMed ID: 32900789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.
    Galli G; Triulzi T; Proto C; Signorelli D; Imbimbo M; Poggi M; Fucà G; Ganzinelli M; Vitali M; Palmieri D; Tessari A; de Braud F; Garassino MC; Colombo MP; Lo Russo G
    Lung Cancer; 2019 Jun; 132():72-78. PubMed ID: 31097097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
    Cortellini A; Ricciuti B; Facchinetti F; Alessi JVM; Venkatraman D; Dall'Olio FG; Cravero P; Vaz VR; Ottaviani D; Majem M; Piedra A; Sullivan I; Lee KA; Lamberti G; Hussain N; Clark J; Bolina A; Barba A; Benitez JC; Gorría T; Mezquita L; Hoton D; Aboubakar Nana F; Besse B; Awad MM; Pinato DJ
    Ann Oncol; 2021 Nov; 32(11):1391-1399. PubMed ID: 34400292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
    Pons-Tostivint E; Hulo P; Guardiolle V; Bodot L; Rabeau A; Porte M; Hiret S; Demontrond P; Curcio H; Boudoussier A; Veillon R; Mayenga M; Dumenil C; Chatellier T; Gourraud PA; Mazieres J; Bennouna J
    Cancer Immunol Immunother; 2023 Jun; 72(6):1881-1890. PubMed ID: 36690799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
    Pérol M; Felip E; Dafni U; Polito L; Pal N; Tsourti Z; Ton TGN; Merritt D; Morris S; Stahel R; Peters S
    Ann Oncol; 2022 May; 33(5):511-521. PubMed ID: 35218887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study.
    Saltman DL; Varga MG; Nielsen TJ; Croteau NS; Lockyer HM; Jain AL; Vidal GA; Hout DR; Schweitzer BL; Seitz RS; Ross DT; Gandara DR
    Clin Lung Cancer; 2023 Mar; 24(2):137-144. PubMed ID: 36564297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma.
    Hong L; Lewis WE; Nilsson M; Patel S; Varghese S; Rivera MJ; Du RR; Chen P; Kemp HN; Rinsurongkawong W; Heeke S; Spelman AR; Elamin YY; Negrao MV; Sepesi B; Gibbons DL; Lee JJ; Wu J; Vokes NI; Heymach JV; Zhang J; Le X
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
    Blasi M; Kuon J; Lüders H; Misch D; Kauffmann-Guerrero D; Hilbrandt M; Kazdal D; Falkenstern-Ge RF; Hackanson B; Dintner S; Faehling M; Kirchner M; Volckmar AL; Kopp HG; Allgäuer M; Grohé C; Tufman A; Reck M; Frost N; Stenzinger A; Thomas M; Christopoulos P
    Eur J Cancer; 2024 Mar; 199():113556. PubMed ID: 38271745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
    Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.